Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535166 · ClinicalTrials.gov registry record · Phase 2
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
A Phase 2 study of Medulloblastoma, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT05535166 is a Phase 2 study of Medulloblastoma that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 130 participants, roughly in line with the 136-participant average among 29 other Medulloblastoma trials with a reported enrollment target. The trial reports 10 study locations across 7 states.
The verdict
NCT05535166, a Phase 2 study of Medulloblastoma, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Vincristine
- PROCEDURE Surgical resection
- DRUG Methotrexate
- PROCEDURE Ommaya/VPS
Study Locations (10)
Texas
- UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital - Houston
Florida
- Orlando Health Arnold Palmer Hospital for Children - Orlando
- St. Joseph's Children's Hospital - Tampa
California
- Lucille Packard Children's Hospital Stanford - Palo Alto
Michigan
- C.S. MOTT Children's Hospital, University of Michigan - Ann Arbor
Minnesota
- Children's Hospital and Clinics of Minnesota - Minneapolis
Tennessee
- St. Jude Children's Research Hospital - Memphis
Utah
- Primary Children's Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2035-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05535166
The ClinicalTrials.gov registry entry for NCT05535166 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 136-participant average among 29 other Medulloblastoma trials with a reported enrollment target. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medulloblastoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT05535166 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05535166 about?
NCT05535166 is a clinical study titled "Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma". This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
What is the current status of trial NCT05535166?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2022-12-20. Estimated completion is 2035-07.
What conditions does trial NCT05535166 study?
This clinical trial studies the following conditions: Medulloblastoma.
What interventions are being tested in trial NCT05535166?
The interventions under investigation include: Cisplatin (DRUG), Vincristine (DRUG), Surgical resection (PROCEDURE), Methotrexate (DRUG), Ommaya/VPS (PROCEDURE).
Who is sponsoring clinical trial NCT05535166?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535166 being conducted?
This trial has 10 study locations across California, Florida, Michigan, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
RECRUITING · Phase 2
-
Digoxin Medulloblastoma Study
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Methionine PET/CT Studies In Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.